Modulation of apolipoprotein (a) expression

Details Modulation of apolipoprotein (a) expression Modulation of apolipoprotein (a) expression

2007-07-30

2010-06-22

Bowman, Amy (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C536S024500, C536S024330, C536S024310

Reexamination Certificate

active

07741305

ABSTRACT:
Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.

REFERENCES:
patent: 5721138 (1998-02-01), Lawn
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5866551 (1999-02-01), Benoit et al.
patent: 6008344 (1999-12-01), Bennett et al.
patent: 6080580 (2000-06-01), Baker et al.
patent: 6512161 (2003-01-01), Rouy et al.
patent: 6515191 (2003-02-01), Lal et al.
patent: 6525191 (2003-02-01), Ramasamy et al.
patent: 6573050 (2003-06-01), Ben-David et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6613567 (2003-09-01), Bennett et al.
patent: 6809193 (2004-10-01), McKay et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0104410 (2003-06-01), Mittmann
patent: 2003/0119766 (2003-06-01), Crooke
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2004/0242516 (2004-12-01), Crooke
patent: 2006/0281698 (2006-12-01), Crooke et al.
patent: WO 96/09392 (1996-03-01), None
patent: WO 97/17371 (1997-05-01), None
patent: WO 99/34016 (1999-07-01), None
patent: WO 99/35241 (1999-07-01), None
patent: WO 03/014307 (2003-02-01), None
patent: WO 2004/031237 (2004-04-01), None
patent: WO 2004/108916 (2004-12-01), None
patent: WO 2005/000201 (2005-01-01), None
U.S. Appl. No. 60/475,402, filed Jun. 2, 2003, Crooke et al.
Agrawal et al., “Antisense oligonucleotides: towards clinical trials” TIBTECH (1996) 14:376-387.
Anderson et al., “A comparison of selected mRNA and protein abundances in human liver” Electrophoresis (1997) 18:533-537.
Braasch et al., “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression” Biochemistry (2002) 41:4503-4510.
Branch, “A Good Antisense Molecule is Hard to Find” TIBS (1998) 23:45-50.
Callow et al., “Expression of human apolipoprotein B and assembly of lipoprotein (a) in transgenic mice” PNAS (1994) 91:2130-2134.
Chiesa et al., “Reconstitution of Lipoprotein (a) by Infusion of Human Low Density Lipoprotein into Transgenic Mice Expressing Human Apolipoprotein (a)” J. of Biological Chem. (1992) 267:24369-24374.
Chin, “On Preparation and Utilization of Isolated and Purified Oligonucleotides” Katherine R. Everett Law Library of the University of North Carolina, Mar. 14, 2002.
Deverre et al., “A competitive enzyme hybridization assay for plasma determination of phosphodiester and phosphorothioate antisense oligonucleotides” Nucleic Acids Res. (1997) 25:3584-3589.
Dias et al., “Potential roles of antisense oligonucleotides in cancer therapy. The example of bcl-2 antisense oligonucleotides.” European J. of Pharmaceutics and Biopharmaceutics (2002) 54:263-269.
European Search Report from EP 04751768.5 dated Nov. 3, 2006 (ISPH-0595EP).
European Search Report from EP 02794670.6 dated Jan. 24, 2005 (ISPH-0690EP).
Frank et al., “The apolipoprotein (a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen” Hum. Genet. (1988) 79:352-356.
Frank et al., “Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo” Gene Therapy (2001) 8:425-430.
Fritz et al., “Cationic Polystyrene Nonoparticles: Preparation and Characterization of a Model Drug Carrier System for Antisense Oligonucleotides” Journal of Colloid and Interface Science (1997) 195:272-288.
Gewirtz et al., “Facilitating oligonucleotide delivery: Helping antisense deliver on its promise” PNAS (1996) 93:3161-3163.
Grainger et al., “Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein (a) mice” Nature (1994) 370:460-462.
Green et al., “Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease” J. Am. Coll. Surg. (2000) 191:93-105.
Hajjar et al., “The role of lipoprotein (a) in atherogenesis and thrombosis” Annu. Rev. Med. (1996) 47:423-442.
International Search Report from PCT/US2002/024920 dated Jul. 16, 2003 (ISPH-0690).
International Search Report from PCT/US2004/014540 dated Jan. 25, 2006 (ISPH-0595WO2).
Jen, “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies” Stem Cells (2000) 18:307-319.
Katan et al., “Characteristics of human hypo- and hyperresponders to dietary cholesterol” Am. J. Epidemiol. (1987) 125:387-399.
Kostner et al., “Lipoprotein (a): Still an Enigma?” Current Opinion in Lipidology (2002) 13:391-396.
Lawn et al., “Atherogenesis in transgenic mice expressing human apolipoprotein (a)” Nature (1992) 360:670-672.
McLean et al., “cDNA sequence of human apolipoprotein (a) is homologous to plasminogen” Nature (1987) 330:132-137.
Milligan et al., “Current Concepts in Antisense Drug Design” J. Medicinal Chemistry (1993) 36: 1923-1927.
Morishita et al., “Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein (a) selectively inhibit apolipoprotein (a) but not plasminogen gene expression” Circulation (1998) 98:1898-1904.
Nowak-Gottl et al., “Lipoprotein (a): its role in childhood thromboembolism” Pediatrics (1997) 99:E11.
Office Action from U.S. Appl. No. 09/923,515 dated Aug. 7, 2001.
Office Action from U.S. Appl. No. 09/923,515 dated Mar. 19, 2003.
Office Action from U.S. Appl. No. 09/923,515 dated Mar. 9, 2004.
Office Action from U.S. Appl. No. 09/923,515 dated Nov. 3, 2004.
Office Action from U.S. Appl. No. 09/923,515 dated Apr. 6, 2005.
Office Action from U.S. Appl. No. 10/684,440 dated Oct. 15, 2003.
Office Action from U.S. Appl. No. 10/684,440 dated Jan. 26, 2005.
Ohmichi et al., “The virtues of self-binding: high sequence specificity for RNA cleavage by self-processed hammerhead ribozymes” Nucleic Acids Res. (2000) 28:776-783.
Opalinski et al., “Nucleic-Acid Therapeutics: Basic Principles and Recent Applications” Nature Reviews (2002) 1:503-514.
Prosnyak et al., “Substitution of 2-aminoadenine and 5-methylcytosine for adenine and cytosine in hybridization probes increases the sensitivity of DNA fingerprinting” Genomics (1994) 21:490-494.
Rainwater et al., “Lipoprotein Lp (a): effects of allelic variation at the LPA locus” J. Exp. Zool. (1998) 282:54-61.
Sandkamp et al., “Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age” Clin. Chem. (1990) 36:20-23.
Seed et al., “Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia” N. Engl. J. Med. (1990) 322:1494-1499.
Skerra, “Phosphorothioate primers improve the amplification of DNA sequences by DNA polymerase with proofreading activity” Nucleic Acids Res. (1992) 20:3551-3554.
Tamm et al., “Antisense therapy in oncology: new hope for an old idea?” The Lancet (2001) 358:489-497.
Vessby et al., “Diverging Effects of Cholestyramine on Apolipoprotein B and Lipoprotein Lp (a)” Atherosclerosis (1982) 44:61-71.
Weintraub et al., “Antisense RNA and DNA” Scientific American (1990) 40-46.
Yang et al., “Transforming Growth Factor-B1 Inhibits Human Keratinocyte Proliferation by Upregulation of a Receptor-Type Tyrosine Phosphatase R-PTP-K Gene Expression” Biochem. Biophys. Res. Commun. (1996) 228:807-812.
Berg et al. “Spontaneous Atherosclerosis in the Proximal Aorta of LPA Transgenic Mice on a Normal Diet,” Atherosclerosis (2002) vol. 163:99-104.
Crooke et al., “Basic Principles of Antisense Thera

Affiliated with

Also associated with

Rating

Modulation of apolipoprotein (a) expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulation of apolipoprotein (a) expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of apolipoprotein (a) expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4194938